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Aims. To compare the baseline characteristics of a population-based cohort of patients with ankylosing spondylitis (AS)
commencing biological therapy to the reported characteristics of bDMARD randomised controlled trials (RCTs) participants.
Methods. Descriptive analysis of AS participants in the Australian Rheumatology Association Database (ARAD) who were
commencing bDMARD therapy. Results. Up to December 2008, 389 patients with AS were enrolled in ARAD. 354 (91.0%) had
taken bDMARDs at some time, and 198 (55.9%) completed their entry questionnaire prior to or within 6 months of commencing
bDMARDs. 131 (66.1%) had at least one comorbid condition, and 24 (6.8%) had a previous malignancy (15 nonmelanoma
skin, 4 melanoma, 2 prostate, 1 breast, cervix, and bowel). Compared with RCT participants, ARAD participants were older, had
longer disease duration and higher baseline disease activity. Conclusions. AS patients commencing bDMARDs in routine care are
significantly diﬀerent to RCT participants and have significant baseline comorbidities.
Copyright © 2009 John Oldroyd et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. Introduction
Ankylosing spondylitis is a chronic inflammatory rheumatic
disorder predominantly aﬀecting the spine with a reported
prevalence in Caucasian populations varying between 0.05%
to 0.23% [1]. AS has a substantial impact upon physical and
emotional functioning and is associated with a progressive
decline in quality of life [2, 3]. In those with severe disease,
mortality is increased [4]. Extraspinal features may include
peripheral arthritis, uveitis, enteritis, and psoriasis. Tradi-
tional disease modifying antirheumatic drugs (DMARDs)
have been ineﬀective for the spinal component of the disease
with the mainstay of treatment consisting of exercise therapy
[5] and nonsteroidal anti-inflammatory drugs [6, 7].
Recently, biological disease modifying antirheumatic
drugs (bDMARDs) including the tumor necrosis factor
(TNF alpha) inhibitors etanercept, infliximab, and adali-
mumab have been shown to reduce disease activity and
results in improvements in pain, function, and quality of
life in AS [8–12]. Randomized controlled trials (RCTs) have
established large treatment benefits for spinal pain, mobility,
and function as well as improvements in extraspinal features
[9, 10, 13]. Whether these eﬀects will be fully realized and
maintained in routine care remains to be determined as
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the trials have been of relatively short duration (e.g., 24–
54 weeks) and have excluded important patient groups (i.e.,
patients under the age of 18 years and those with a history
of cardiac, renal, hepatic, psychiatric, or neurologic disease
or history of malignancy); and baseline comorbidities of trial
participants have not been reported in detail [11, 14–16].
To address the limitations of clinical trials and determine
the long-term safety and eﬀectiveness of bDMARD therapy
in AS in a “real life” context, population-based registries
that allow careful longitudinal observation in routine clinical
care have been established in several countries. These include
the Australian Rheumatology Association Database (ARAD)
[17], the British Society for Rheumatology Biologics Registry
(BSRBR) [18], the Spanish Registry for adverse events of
biological therapies in Rheumatic Diseases (BIOBADASER)
[19], the Danish Database for Biological Therapies (DAN-
BIO) [20], the National Register for Biological Treatment in
Finland (ROB-FIN) [21], and the Norway Disease Modifying
AntiRheumatic Drugs Register (NOR-DMARD) [22].
In determining the long-term safety and eﬀectiveness of
bDMARDs for AS, it is important to consider the potential
confounding eﬀects of other comorbid conditions. Unless
comorbid conditions are considered, adverse events may be
incorrectly attributed to bDMARD therapy. Comorbidity
has been shown to be a significant predictor of health
outcomes in patients with rheumatoid arthritis [23, 24],
with premature mortality largely attributed to cardiovascular
disease, infection, and malignancy [25]. Several registries,
including our own, have reported a high prevalence of
comorbid conditions in patients with rheumatoid arthritis
commencing bDMARDs [20, 26, 27] but the prevalence
of comorbid conditions in patients with AS commencing
bDMARD therapy has not, thus far, been widely reported.
Before bDMARDs can be prescribed under government-
subsidized schemes in Australia certain stringent criteria
must be met. These include fulfilment of the modified New
York criteria for definite AS [28] and failure to respond,
over a three-month period, to two or more NSAIDs and an
exercise program. Failure to respond is defined as a Bath
Ankylosing Spondylitis Disease Activity Index (BASDAI) of
at least 4.0 and raised inflammatory markers (erythrocyte
sedimentation rate (ESR) >25 mm/hour and/or C-reactive
protein (CRP) >10.0 mg/L) [29]. Similarly restrictive criteria
exist in the UK [30].
In contrast to some other countries [31], previous and/or
current malignancy is not an absolute contraindication
to prescribing bDMARDs in Australia although increased
vigilance is recommended for patients who have a history
of malignancy [32]. The incidence and types of malignan-
cies that occur in Australia diﬀer somewhat from those
reported elsewhere providing an added imperative to collect
Australian data rather than rely on the observations from
other registries. For example, Australia has the highest
incidence of both melanoma and nonmelanoma skin cancers
(NMSCs) in the world attributed to the outdoor lifestyle of
a predominantly fair-skinned population and more recently
to the reduced ozone layer in this region [33, 34]. It also
has a comparatively higher risk of skin cancer in organ
transplant recipients who also receive immunosuppressive
agents [35] and we have previously reported a threefold
increase in the risk of melanoma in Australian methotrexate-
treated patients with rheumatoid arthritis compared with the
general population [36].
The aim of this study was to describe the baseline
characteristics including comorbidities of a population-
based cohort of Australian patients with AS participating
in ARAD who are commencing bDMARDs and to compare
them to the baseline characteristics of participants enrolled
in published bDMARD RCTs in AS.
2. Methods
2.1. ARAD Design. The structure and governance of ARAD
has been described previously [17]. Briefly, ARAD was estab-
lished by the Australian Rheumatology Association (ARA)
in 2003 as a voluntary registry to collect longitudinal health
outcomes data from Australian patients with inflammatory
arthritis treated with bDMARDs. Recruitment of controls
(those not prescribed biologics) commenced in 2000 and is
ongoing although numbers are small to date. The primary
goal of ARAD is to determine the long-term eﬀectiveness and
safety of bDMARDs in routine clinical practice.
Ethical approval has been granted by the Institutional
Human Research Ethics Committees of Cabrini Hospital,
Melbourne; Northern Sydney Health; South Eastern Sydney
and Illawarra Area Health; Australian Government Depart-
ment of Veterans Aﬀairs; Monash University; Royal Chil-
dren’s Hospital, Melbourne; NSW Population and Health
Services Research Ethics; Tasmanian Human Research Ethics
Committee; Australian Institute of Health and Welfare;
Cancer Institute of NSW; Department of Health (CHIC)
Western Australia; St Vincent’s Hospital, Melbourne; The
Children’s Hospital, Westmead; Department of Health South
Australia Human Research Ethics Committee; Queensland
Cancer Registry; the Tasmanian Cancer Registry; the Vic-
torian Cancer Registry; the ACT Cancer Registry; Northern
Territory Cancer Registry, the New South Wales Central
Cancer Registry, the Western Australian Cancer Registry,
and the National Cancer Statistics Clearing House. All
participants provide written informed consent.
2.2. Data Collection. Data collected from the rheumatologist
at baseline includes the TNF alpha inhibitor prescribed, ESR,
CRP, and the Bath Ankylosing Spondylitis Disease Activity
Index (BASDAI) [37]. The BASDAI is a quick, reliable, self-
administered instrument used to determine disease activity
in patients with AS. It measures severity of fatigue, spinal
and peripheral joint pain, localized tenderness, and morning
stiﬀness and is scored from 0 to 10 (0 = best).
All ARAD participants complete a detailed entry ques-
tionnaire and six-month followup questionnaires returned
in a reply paid envelope. Returned data are scanned into
the database and subject to rigorous quality control and
data validation processes to ensure database quality. Data
collected from the participants include: demographic details,
disease duration and severity, self-reported past and current
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medical history including cancers and other chronic con-
ditions, use of antirheumatic drugs, smoking, and alcohol
history, generic measures of quality of life including the Short
Form-36 (SF-36)(subscale scores range 0–100, 100 = perfect
health) [38], and Assessment of Quality of Life (AQoL)
(score range 0-1, 1 = full health) [39], and arthritis-specific
disability assessed by the Health Assessment Questionnaire
modified for spondyloarthropathies (S-HAQ) (score range
0–3, 0 = no disability) [40].
For the purpose of this study, the baseline characteristics
and health-related quality of life of AS patients commencing
bDMARDS were extracted from the last questionnaire
completed prior to commencing bDMARD therapy. For
participants who enrolled in ARAD after starting therapy,
BASDAI, ESR, and CRP at the time of starting therapy were
obtained from the referring rheumatologist and comorbidi-
ties were only considered if data were available either prior to
or within 6 months of the start of bDMARDS. Health-related
quality of life data prior to commencing bDMARD therapy
was unavailable for these participants.
2.3. Verification of Malignancy. We verified all self-reported
malignancies identified prior to commencement of
bDMARDs by record linkage to the National Cancer
Statistics Clearing House (NCSCH) and the Victorian
State Cancer Registry (VCR) in 2007. The NCSCH is a
repository of data for each state cancer registry in Australia
apart from the state of Victoria. Since 1982 the state
registries have collected details of all malignancies apart
from nonmelanocytic skin cancers, and notification of
malignancy to the relevant state registry is mandatory
by law. Virtual complete ascertainment is achieved by
notification from pathology laboratories, hospital medical
record departments, and by screening of death certificates.
The International Classification of Diseases—9th Revision
(ICD-9) is used to code site of malignancy [41] and the
ICD-O morphology rubrics to code histological type
[42, 43]. At the time of the study the NCSCH and VCR were
complete up until the end of 2003 and 2005, respectively.
Self-reported malignancies prior to 1982 and after 2003/2005
for the NCSCH and VCR, respectively, and all self-reported
nonmelanocytic skin cancers were verified by obtaining
pathology reports and/or confirmation by the treating
doctor.
2.4. Identification of Published AS RCTs of bDMARDs. A
PubMed search was conducted using the terms “ankylosing
spondylitis” and the names of the three TNF inhibitors
individually “infliximab” or “etanercept” or “adalimumab”
to identify relevant AS RCTs of bDMARDs. Relevant baseline
participant data were extracted from the RCTs and weighted
means calculated for comparison with the ARAD data.
2.5. Data Analysis. Responses to the health related quality
of life instruments (SF-36, EuroQoL and AQoL) were coded
according to the standard published algorithms as described
by the developers [38, 39, 44]. Independent sample t-tests
were used to compare data in ARAD with that reported in
Table 1: Baseline demographic and clinical characteristics of AS
patients enrolled in ARAD who have been exposed to biological
therapy (n = 354)∗.
Mean (SD) age, years 45.1 (12.3)
Males (%) 254 (71.8)
Mean (SD) disease duration, years (n = 299) 18.5 (12.1)
Mean (SD) delay in diagnosis, years (n = 310) 5.5 (7.1)
Concomitant DMARDs, N (%) 72 (20.3)
Methotrexate (oral or IM) 50 (14.1)
Salazopyrin 22 (6.2)
Leflunomide 5 (1.4)
Currently taking prednisolone, N (%) 42 (11.9)
Smoking history, N (%)
Current 61 (17.2)
Past 98 (27.7)
Never 195 (55.1)
Alcohol consumption, N (%)
Daily 62 (17.5)
Sometimes 217 (61.2)
Never 75 (21.2)
Mean (SD) ESR, mm/hr (n = 274) 35.4 (24.8)
Mean (SD) CRP, mg/L (n = 300) 31.8 (31.9)
BASDAI (0–10, 0 = best) (n = 301) 7.6 (4.5)
Mean (SD) S-HAQ score (0–3, 0 no = disability)∗∗ 0.86 (0.60)
Mean (SD) AQoL score (0-1, 1 = full health)∗∗ 0.55 (0.25)
SF-36 score∗∗
Physical component 36.2 (10.6)
Mental component 45.1 (11.1)
∗
unless otherwise indicated
∗∗n = 198 in those prior to or within 6 months of commencing bDMARDS
previously conducted RCTs. All data were analysed using
STATA (Version 10.0, Stata Corporation, College Station,
Tex, USA).
3. Results
To 11th December 2008, 3025 participants were enrolled in
ARAD. They included 2366 with rheumatoid arthritis, 389
with AS, 186 with psoriatic arthritis, and 83 with juvenile
idiopathic arthritis. 201 (75.2%) rheumatologists from all
Australian states and territories had contributed patients.
Thirty-five out of the 389 AS participants (9%) had never
taken bDMARD therapy and were excluded from further
analysis. At the time of the analysis, 136 were currently
taking etanercept, 124 were taking infliximab, 60 were taking
adalimumab (n = 320), and 34 were not currently taking
bDMARDs.
The baseline characteristics of the 354 AS participants
who commenced biological therapy are summarised in
Table 1.
At the time of commencement of bDMARD therapy,
72 (20.3%) participants were taking at least one DMARD
(65 were taking one DMARD and 7 were taking two), most
commonly methotrexate (n = 50, 14.1%) or salazopyrin
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Figure 1: Number of comorbid conditions in patients with
ankylosing spondylitis commencing biological therapy (n = 198).
Table 2: Self-reported comorbid conditions among ankylosing
spondylitis patients commencing biological therapy (n = 198).
Condition N (%)
Gastrointestinal disease 62 (31.3)
Hypertension 51 (25.8)
Eye disorder 32 (16.1)
Hypercholesterolaemia 31 (15.6)
Depression 28 (14.1)
Anaemia or other blood disorder 28 (14.1)
Lung disease 21 (10.6)
Neurological disorder 18 (9.0)
Osteoporosis 17 (8.6)
Alcohol and drug 13 (6.6)
Other heart disease 13 (6.5)
Liver disease 7 (3.5)
Thyroid disorder 7 (3.5)
Diabetes Mellitus 7 (3.5)
Cerebrovascular accident 5 (2.5)
Kidney disease 4 (2.0)
Angina 4 (2.0)
Mental illness other than depression 4 (2.0)
Tuberculosis 2 (1.0)
(n = 22, 6.2%); while 42 (11.9%) participants were taking
prednisolone. Participants had evidence of active disease
(mean (SD) BASDAI score 7.6 (4.5). Of those with AS who
had ever taken bDMARDs (n = 354), quality of life data
at baseline was available for 198 (56%) who had enrolled
in ARAD prior to or within 6 months of commencing
bDMARDs. They had moderate disability (mean (SD) S-
HAQ 0.86 (0.60) and impaired quality of life, mean (SD)
AQoL score 0.55 (0.25); SF-36 Physical Component score
36.2 (10.6), SF-36 Mental Component score 45.1 (11.1)).
At least one comorbid condition (past or current)
was reported by 131 (66.1%) participants and 91 (46.0%)
reported more than one (Figure 1).
The most frequently self-reported comorbidities were
gastrointestinal disease reported by 61 (31.3%) participants,
hypertension 51 (25.8%), eye disorders 32 (16.1%), dyslipi-
daemia 31 (15.6%), and depression 28 (14.1%) (Table 2).
Twenty four participants (6.8%) had a previous malig-
nancy: nonmelanoma skin cancer (n = 15), melanoma (n =
4), prostate cancer (n = 2), breast cancer (n = 1), cervical
cancer (n = 1), and bowel cancer (n = 1).
We identified 4 published RCTs of bDMARDs in AS
(Table 3) [11, 14–16]. Compared with participants in previ-
ous RCTs, there was a similar proportion of males (71.8%
versus 73.8%, P = .46), but ARAD participants were older
(mean (SD) age 45.1 (12.3) years versus 41.9 (6.0) years, P <
.001), had a longer disease duration (mean (SD) duration
18.5 (12.1) years versus 12.6 (5.0) years, P < .001) and had
higher baseline BASDAI scores (mean (SD) 7.6 (4.5) versus
4.1 (0.83), P < .001).
4. Discussion
We have described the baseline comorbidities of a
population-based cohort of patients with AS commencing
biologic therapy extracted from a national biologic registry.
As 75% of Australian rheumatologists contribute patients
to ARAD and as all states and territories are represented,
we think that our patient sample is representative of the
Australian population. Two thirds of our sample reported
having at least one comorbid condition, almost half (46.0%)
had more than one, and 6.8% had a history of malignancy.
In comparison with participants in RCTs of bDMARDs for
AS, ARAD AS participants commencing biological therapy
were older, had longer duration of disease, and had more
severe disease at the time of commencement of bDMARDs.
They also had significant disability and impaired quality of
life.
To put the high level of baseline comorbidity into
context, Figure 2 shows comparable data for ARAD partici-
pants with rheumatoid arthritis (RA) commencing biologics.
Despite the younger age of the AS cohort (mean age 45.1
(12.3) versus 57.0 (12.5) years for the RA cohort, P =
.001) the prevalence of at least one comorbid condition
was comparable [27] and it is also comparable to the
reported baseline comorbidity of RA patients commencing
bDMARDs elsewhere [23, 26].
The significantly greater disease activity at commence-
ment of bDMARDs in our AS cohort compared with
RCTs [11, 14–16] most likely reflects the stringent PBS
requirements for approval of bDMARDs for AS in Australia.
Our patients also appear to have greater disease activity
at bDMARD commencement than patients commencing
bDMARDs in routine care in other settings. For example,
a Spanish study of patients with AS commencing biologic
therapy reported mean BASDAI scores of 4.5 (versus 7.1 in
our study) [45].
Comparable eﬃcacy between RCTs and clinical practice
is hardly ever achieved due in part to patient selection, dif-
ferences in comedications and comorbidities and treatment
adherence [46]. Participants in RCTs are likely to be diﬀerent
in some important respects to individual patients seen in
clinical practice since minority groups, older individuals,
and those at risk of adverse events may be deliberately
excluded. The diﬀerences we observed may also have been
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Figure 2: Self-reported comorbidities in ankylosing spondylitis
(n = 198) and rheumatoid arthritis (N = 624∗).
accentuated by the lack of available treatment options prior
to the introduction of bDMARD therapy for AS. Over time,
it is likely that the average age and disease duration of those
prescribed bDMARDs will diminish as newly diagnosed
patients who fulfil criteria are treated earlier.
Two of the four trials excluded participants with a history
of malignancy [11, 15] and a third excluded patients with
an active malignancy in the 5 years prior to the study [16].
The fourth trial did not specify malignancy as an exclu-
sion criterion, and no details regarding presence/absence
of malignancy in participants at baseline were reported
[14]. We found that 24 (6.8%) AS patients commencing
bDMARD therapy in our study had a verified history of
malignancy including 15 with nonmelanoma skin cancer and
4 with melanoma. The true prevalence of nonmelanoma skin
cancers is likely to be higher but this data is not captured by
Australian state registries and we only included self-reported
cancers that we could verified by pathology or doctor report.
Available data on risk of malignancy in AS are limited
and mainly confined to the increased cancer risk observed
in patients with AS subjected to radiation treatment [47].
Recent Swedish population-based studies have not found an
increased risk of lymphoma or malignancies overall [48, 49].
It is also unknown whether biologic therapy confers any
increased risk of malignancy or recurrence of malignancy in
AS. These risks may only be determined by careful long-term
comparisons of exposed and unexposed populations.
There are several potential limitations of our study.
While we were able to verify the validity of self-reported
malignancies, we did not verify the validity of self-report
of comorbid conditions. As reported previously, ARAD
data are derived predominantly from patient questionnaire
[17]. At the time that ARAD was established, there were
concerns about the administrative burden of applying for
biological therapy and rheumatologists were asked to provide
a minimum of information at baseline only. Nevertheless,
baseline comorbidities reported by patients with RA in
ARAD are comparable to those reported in other studies
[18].
A second limitation of our study is that we have
not routinely collected data about the presence/absence of
extra spinal features of AS such as uveitis, psoriasis, and
inflammatory bowel disease, due in part to the fact that
ARAD was originally set up for RA. It is likely that some
self-reported comorbidities in our study are likely to relate
to these extraspinal manifestations of the disease.
5. Conclusion
We found that a population-based cohort of patients
with AS commencing biological therapy and participating
in a national biologics registry already has significant
comorbidities. Despite their younger age, the prevalence of
comorbidities was comparable to that seen in a population-
based RA cohort commencing bDMARDs. These findings
have important implications for monitoring patients while
on therapy, assessing the long-term health outcomes of
bDMARD therapy and attribution of adverse events. We
also found that participants in RCTs of bDMARDs for
AS were not representative of Australian patients with AS
commencing bDMARDs in routine care. As well as being
older, having longer disease duration, and more active
disease, 6.8% also had a history of verified malignancy. These
findings highlight the importance of systematically collecting
postmarketing longitudinal outcome data for bDMARDs in
routine care.
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